197 related articles for article (PubMed ID: 32631802)
1. Safety and efficacy of levosimendan in patients with cardiac amyloidosis.
Aimo A; Rapezzi C; Arzilli C; Vergaro G; Emdin M
Eur J Intern Med; 2020 Oct; 80():114-116. PubMed ID: 32631802
[No Abstract] [Full Text] [Related]
2. Levosimendan in patients with decompensated heart failure.
Rosa EM; Osório AP; Scopel L
Arq Bras Cardiol; 2008 Aug; 91(2):119. PubMed ID: 18709265
[No Abstract] [Full Text] [Related]
3. Can we believe in levosimendan?
Follath F
Arq Bras Cardiol; 2008 Mar; 90(3):146-7. PubMed ID: 18392391
[No Abstract] [Full Text] [Related]
4. Heart failure update.
Gomes UC; Cleland JG
Eur J Heart Fail; 1999 Aug; 1(3):301-2. PubMed ID: 10935680
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
[TBL] [Abstract][Full Text] [Related]
6. Levosimendan use in several scenarios of acute heart failure.
Tavares M; Andrade AC; Mebazaa A
Arq Bras Cardiol; 2008 Mar; 90(3):211-5. PubMed ID: 18392402
[TBL] [Abstract][Full Text] [Related]
7. Levosimendan in acute pulmonary embolism.
Powell BP; Simes D
Anaesth Intensive Care; 2007 Oct; 35(5):771-2. PubMed ID: 17933166
[TBL] [Abstract][Full Text] [Related]
8. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
Cavusoglu Y
Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
[TBL] [Abstract][Full Text] [Related]
9. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
[TBL] [Abstract][Full Text] [Related]
10. BELIEF: believe it or not.
Beck-da-Silva L; Fuchs FD
Arq Bras Cardiol; 2008 Aug; 91(2):119-21. PubMed ID: 18709264
[No Abstract] [Full Text] [Related]
11. Levosimendan.
Mason P
Intensive Crit Care Nurs; 2003 Dec; 19(6):370-1. PubMed ID: 14637297
[No Abstract] [Full Text] [Related]
12. Levosimendan for heart-operated patients: what is the state of the art?
Tagarakis GI; Tsilimingas NB
Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):22-4. PubMed ID: 19149702
[TBL] [Abstract][Full Text] [Related]
13. Tricuspid valve replacement and levosimendan.
Cicekcioglu F; Parlar AI; Altinay L; Yay K; Katircioglu SF
Gen Thorac Cardiovasc Surg; 2008 Nov; 56(11):559-62. PubMed ID: 19002757
[TBL] [Abstract][Full Text] [Related]
14. Positive inotropy for acute heart failure complicating myocardial infarction.
Coats AJ
Eur Heart J; 2002 Sep; 23(18):1405-6. PubMed ID: 12208215
[No Abstract] [Full Text] [Related]
15. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Earl GL; Fitzpatrick JT
Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan as a bridge to heart transplant: a real alternative.
Goirigolzarri-Artaza J; Restrepo-Córdoba MA
Rev Esp Cardiol (Engl Ed); 2024 Apr; 77(4):302-303. PubMed ID: 38104926
[No Abstract] [Full Text] [Related]
17. [Levosimendan and low cardiac output syndrome. Does mortality really decrease? ].
Alvarez J
Rev Esp Cardiol; 2008 May; 61(5):454-7. PubMed ID: 18462647
[No Abstract] [Full Text] [Related]
18. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
Lehtonen L
Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
Biala A; Martonen E; Kaheinen P; Levijoki J; Finckenberg P; Merasto S; Louhelainen M; Muller DN; Luft FC; Mervaala E
Hypertens Res; 2010 Oct; 33(10):1004-11. PubMed ID: 20811386
[TBL] [Abstract][Full Text] [Related]
20. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
